Honz Pharmaceutical released its 2026 interim report. During the reporting period, the company's total operating revenue was 145 million yuan, down 37.67 percent year on year, and net profit attributable to the parent company was a loss of 32.77 million yuan. Net cash flow from operating activities was a negative 11.24 million yuan, down 116.94 percent year on year. The company's asset-liability ratio was 48.14 percent, gross margin was 54.73 percent, return on equity was negative 3.78 percent, and diluted earnings per share was negative 0.07 yuan. The number of shareholders was 42,800, and the top ten shareholders held 33.45 percent of the total share capital.
Hainan Honz Pharmaceutical CoCompany reported a net loss of 32.77 million yuan and declining revenue in its interim report.
